Vaarala M H, Lukkarinen O, Marttila T, Kyllönen A P, Porvari K S, Vihko P T
Biocenter Oulu, World Health Organization Collaborating Centre for Research on Reproductive Health, University of Oulu, Finland.
World J Urol. 2000 Dec;18(6):406-10. doi: 10.1007/s003450000159.
This study was aimed at exploring the effect of finasteride, a non-steroidal competitive inhibitor of the enzyme 5alpha-reductase, on 5alpha-reductase type 2 at the mRNA level in human prostate, using an in situ hybridization technique. After randomization, 10 men with benign prostatic hyperplasia (BPH) received oral finasteride (5 mg daily) and five men with BPH received placebo daily. Careful clinical examination was carried out and 2 biopsy samples were taken transrectally before the treatment and after 3, 6, and 12 months of treatment. In situ hybridization was carried out and expression of 5alpha-reductase type 2 mRNA was measured. The results showed that finasteride treatment had no permanent effect on expression of 5alpha-reductase type 2 in prostatic epithelium, compared with placebo treatment. Expression varied during treatment, but there was no clear tendency in this expression. The signal was localized in the epithelial cells. We conclude that finasteride treatment had no clear effect on human 5alpha-reductase type 2 expression in the prostate.
本研究旨在利用原位杂交技术，探讨非甾体类5α-还原酶竞争性抑制剂非那雄胺在mRNA水平对人前列腺组织中2型5α-还原酶的作用。随机分组后，10例良性前列腺增生（BPH）男性患者口服非那雄胺（每日5mg），5例BPH男性患者每日服用安慰剂。治疗前及治疗3、6和12个月后进行仔细的临床检查，并经直肠获取2份活检样本。进行原位杂交并检测2型5α-还原酶mRNA的表达。结果显示，与安慰剂治疗相比，非那雄胺治疗对前列腺上皮中2型5α-还原酶的表达无长期影响。治疗期间表达有所变化，但该表达无明显趋势。信号定位于上皮细胞。我们得出结论，非那雄胺治疗对前列腺中人类2型5α-还原酶的表达无明显影响。
